Categories: NewsPharmaceutical

BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 31 August 2022 16.00 (CEST)

BBS Bioactive Bone Substitutes Oyj  – Managers’ Transactions

____________________________________________

Person subject to the notification requirement

Name: Jalovaara, Pekka

Position: Member of the Board/Deputy member

Issuer: BBS Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20220826100002_2

____________________________________________

Transaction date: 2022-05-23

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 55,862 Unit price: 0.0121 EUR

Aggregated transactions

(1): Volume: 55,862 Volume weighted average price: 0.0121 EUR

____________________________________________

Transaction date: 2022-05-24

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 165,492 Unit price: 0.0085 EUR

Aggregated transactions

(1): Volume: 165,492 Volume weighted average price: 0.0085 EUR

____________________________________________

Transaction date: 2022-05-25

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 4,662 Unit price: 0.006 EUR

(2): Volume: 61,786 Unit price: 0.0043 EUR

Aggregated transactions

(2): Volume: 66,448 Volume weighted average price: 0.00442 EUR

____________________________________________

Transaction date: 2022-05-27

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 142,848 Unit price: 0.0013 EUR

(2): Volume: 71,400 Unit price: 0.0013 EUR

(3): Volume: 17,850 Unit price: 0.0013 EUR

Aggregated transactions

(3): Volume: 232,098 Volume weighted average price: 0.0013 EUR

For more information:

Ilkka Kangasniemi, CEO,
tel. +35840 7080307, e-mail: ilkka.kangasniemi@bbs-artebone.fi

Liisa Hukka, CFO,
tel. +35840 0611038, e-mail: liisa.hukka@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, info@certifiedadviser.se

BBS in brief

BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.

BBS-Bioactive Bone Substitutes Oyj:n shares have been listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

More information: www.bbs-artebone.fi

Staff

Recent Posts

Ascentiz Unveiled Modular Designed Exoskeleton at CES 2026: A Technical Deep Dive into Biomechanical Intelligence

The world's first modular exoskeleton combines quasi-direct-drive hip and cable-drive knee technologies for natural, powerful…

2 hours ago

From Clinical Recovery to Lifelong Empowerment: RoboCT Showcases Integrated Ecosystem Strategy at CES 2026

Leveraging Medical Robotics Heritage, the Company Expands into Consumer Market, Envisioning Exoskeletons as Integral 'New…

2 hours ago

Nanodropper® Now Operating as Mu Medical™, Planned Expansion of Precision Eyecare Platform with Bedo Solutions and Viseon Labs

The consolidated entity will leverage AI and precision engineering to create a comprehensive ecosystem advancing…

2 hours ago

Flo Health’s App Wins Google Play “Best of 2025” Award for Best for Watches in Hong Kong, Taiwan, and Macau

LONDON, Jan. 9, 2026 /PRNewswire/ -- Flo Health, the company behind the globally trusted Flo…

2 hours ago

Gifthealth Celebrates Grand Opening Of New Pharmacy In Mesa

MESA, Ariz., Jan. 9, 2026 /PRNewswire/ -- Gifthealth, a unified digital pharmacy platform, today celebrated the…

2 hours ago

Lucent Health Names Aadam Hussain as Chief Executive Officer Following Brett Rodewald’s Retirement

NASHVILLE, Tenn., Jan. 9, 2026 /PRNewswire/ -- Today, Lucent Health, one of the nation's largest independent…

2 hours ago